Filtered By:
Infectious Disease: Cellulitis
Management: Insurance
This page shows you your search results in order of date.
Order by Relevance | Date
Total 3 results found since Jan 2013.
A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine
Am J Epidemiol. 2022 Feb 12:kwac030. doi: 10.1093/aje/kwac030. Online ahead of print.ABSTRACTThe recombinant herpes zoster vaccine (RZV), approved as a 2-dose series in the U.S. in October 2017, has proven highly effective and generally safe. However, a small risk of Guillain-Barré syndrome (GBS) after vaccination was identified post-approval, and questions remain about other possible adverse events. This data-mining study assessed RZV safety in the U.S. using the self-controlled tree-temporal scan statistic, scanning data on thousands of diagnoses recorded during follow-up to detect any statistically unusual temporal clu...
Source: Am J Epidemiol - February 13, 2022 Category: Epidemiology Authors: W Katherine Yih Martin Kulldorff Inna Dashevsky Judith C Maro Source Type: research
